⌕
Verastem · VSTM · Nasdaq
Tenet 18 · Weak
Compare
$7.70−5.87%At closeTenet 18 · Weak
$7.70−0.48 (−5.87%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Verastem (VSTM) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice

11 figures withheld by our checks. Each blank figure names its reason.

Business engineGrowing fast: revenue compounds ~97.0%/yr (FY21→FY25), net margin −677.6%. Worth your attention in FY25: Share count (+376.8%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲209.1%
30.9
FY21→FY25CAGR +97.0%/yr
Net income ($M)▼60.3%
−209.5
FY21→FY25CAGR —
Free cash flow ($M)▼31.2%
−137.5
FY21→FY25CAGR —
Diluted EPS▲17.5%
−3.02
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+376.8%

14.5mn → 69.3mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.

Capex
$0.0K

−100.0% YoY in FY25 · 0.0% of revenue.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)30.9Revenue−4.6COGS26.3Gross profit−114.6R&D−81.1SG&A−170.1Op income−39.3Tax & other−209.5Net income

-678¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.

Margin trend · direction beats level Gross Operating Net
906845230%sector median net margin ~4%FY21FY25

Net margin -677.6% is below the sector median.

The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
The annual and quarterly statements are struck on share counts that differ by a factor of 0.6846, so per-share figures cannot be compared across the two tables. Each table's per-share figures are on its own share basis.
USD thousands except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
100,296.030,914.010,000.00.02,596.02,053.0▲209.1%+97.0%
Cost of revenue
12,812.04,600.00.00.00.00.0——
Gross profit
87,484.026,314.0—A—A—A—A——
Research & development
180,034.0114,599.081,334.061,356.050,558.039,347.0▲40.9%+30.6%
Selling, general & admin
100,640.081,146.043,622.030,728.024,975.024,115.0▲86.0%+35.4%
Total operating expenses
281,791.0196,443.0124,956.092,084.075,533.063,462.0▲57.2%+32.6%
Operating incomefeeds ROC rank
−194,307.0−170,129.0−114,956.0−92,084.0−72,937.0−61,409.0▼48.0%—
Other income, net
16,180.0−39,342.0−15,496.04,717.0−875.0−9,791.0——
Pretax income
−178,127.0−209,471.0−130,452.0−87,367.0−73,812.0−71,200.0▼60.6%—
Income tax
—0.0185.00.00.0———
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−178,903.0−209,471.0−130,637.0−87,367.0−73,812.0−71,200.0▼60.3%—
Per share
Diluted EPSbuyback-sensitive
−1.64−3.02−3.66−3.96−4.57−4.90▲17.5%—
Diluted shares (mn)
101.2469.3135.7122.0516.1414.54▲94.1%+47.8%
Margins
Gross margin81st pct in Healthcare
87.2%85.1%—A—A—A—A——
Operating margin
−193.7%−550.3%−1149.6%—−2809.6%−2991.2%▲599.2pp—
Net margin8th pct in Healthcare
−178.4%−677.6%−1306.4%—−2843.3%−3468.1%▲628.8pp—
† TTM = trailing four quarters through 2026-09-30.A Withheld: cost of revenue is not on file, so the gross margin is not measured.
FY14 – FY20 · 7 more years
Unlock the full history →
5 more years of statements and CSV export are on Premium, and 7 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-03-04 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Verastem's revenue last fiscal year?

Verastem reported revenue of $30.9M in fiscal 2025, up 209.1% from fiscal 2024.

What was Verastem's net income?

Verastem reported net income of −$209.5M in fiscal 2025, a net margin of −677.6%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.